NMD NEUROMUSCULAR DISORDERS

What this means for you

Not registered yet, but its 15 Jul 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79432115

Mark type

Design + words

Filed

15 Jul 2025

Attorney of record

Julie A. Greenberg

Goods and services

• Class 005 — Pharmaceuticals: Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital care, namely, chemical-pharmaceutical preparations for the reversal of neuromuscular blockade, chemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weakness, chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections
• Class 042 — Scientific and technological services: Scientific and technological services and research, namely, research in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparations, and in the field of identification of drug candidates; drug discovery services; basic research and clinical research, hereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care

Owner

• NMD Pharma A/S, DK

Prosecution history

• 12 Mar 2026 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
• 12 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 12 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 12 Mar 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
• 12 Mar 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
• 26 Feb 2026 — REFUSAL PROCESSED BY IB
• 05 Feb 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 05 Feb 2026 — REFUSAL PROCESSED BY MPU
• 10 Jan 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 09 Jan 2026 — NON-FINAL ACTION WRITTEN
• 09 Jan 2026 — ASSIGNED TO EXAMINER
• 08 Jan 2026 — APPLICATION FILING RECEIPT MAILED
• 08 Jan 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 08 Jan 2026 — LIMITATION FROM ORIGINAL APPLICATION ENTERED
• 04 Sept 2025 — SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB